undamentalytics Newsletter
Sign in

Fulgent Genetics, Inc. income statement

In fiscal 2025, Fulgent Genetics, Inc. reported revenue of $323m, up 13.8% on the year before, operating income of −$91.1m (a -28.2% margin) and net income of −$60.5m. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue11018192133422993619289283323324
Cost of revenue1579111490216252185176192209
Gross profit0512101118332777367104107131115
Research and development14446712242941495457
Selling and marketing13245615243941364350
General and administrative02556615511118988117120
Operating income−1−51−3−5−0290676179−196−74−91−122
Interest expense——————0000−000
Income before tax−1−5−4−3−50292677184−174−52−70−92
Income tax001−10073175421−8−8−7
Net income−4−8−5−3−6−0214507143−168−43−61−84
Diluted EPS————————————−$2.80
Diluted shares (average)—12m14m18m18m19m24m31m31m30m30m31m30m
EBITDA−1−42−2−32293687211−169−49−67−101

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: CSTL vs FLGTFLGT vs SDGRFLGT vs MLABFLGT vs TWST

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Fulgent Genetics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Fulgent Genetics, Inc.